Can Mod­er­na ac­tu­al­ly make a vac­cine for the com­mon cold? (And should it?)

Mod­er­na has spent the last year and a half, since their Covid-19 shots first neared au­tho­riza­tion, steadi­ly an­nounc­ing new vac­cine projects. Most of these have been wel­comed by vac­ci­nol­o­gists and pub­lic health re­searchers, who long strug­gled to get in­dus­try in­ter­est­ed in cer­tain pathogens such as Ni­pah or EBV, de­spite the threat they posed.

But on Tues­day, the mR­NA biotech dis­closed a new pro­gram that had some in the vac­cine world scratch­ing their chins.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.